Build the evidence that changes the decision.
TSCIP helps owners move from ambiguous strategic interest to a defined evidence gate, bounded development action and clearer transaction path.
When TSCIP is useful.
TSCIP is most relevant when a clinical-stage oncology program has credible science or human signal, yet strategic conversations repeatedly stop short of an actionable transaction. The issue may be contribution, patient selection, combination logic, durability, safety, development design, commercial threshold or another decision-specific uncertainty.
The core question
What is the smallest credible evidence package that could change a real strategic decision?
What an asset owner receives.
Partnerability assessment
A decision-focused view of where the asset is strategically actionable and what remains unresolved.
Evidence gate
The strategic question the next evidence tranche should be designed to answer.
Development action
A bounded next step intended to generate decision value rather than simply more data.
Capital-to-inflection
A financing requirement linked to the evidence milestone it is meant to purchase.
Transaction readiness
The information, positioning and diligence issues that should be resolved before re-engagement.
Next action
A practical path to advance, reframe, pause or redirect the transaction thesis.
What owners do not receive.
This separation protects the credibility of buyer review and lets TSCIP convert private evaluation patterns into owner-facing decision intelligence without compromising counterparties.
Selective coverage.
TSCIP does not attempt to cover every oncology program. Coverage is selective and intended for assets where a meaningful strategic uncertainty can be framed and where a credible transaction path may exist if that uncertainty is resolved.
Discuss an asset
Initial inquiries should remain non-confidential until both sides agree otherwise.
partner@nectid.com →